Impairment of interferon regulatory factor-3 activation by hepatitis C virus core protein basic amino acid region 1  by Inoue, Kazuaki et al.
Biochemical and Biophysical Research Communications 428 (2012) 494–499Contents lists available at SciVerse ScienceDirect
Biochemical and Biophysical Research Communications
journal homepage: www.elsevier .com/locate /ybbrcImpairment of interferon regulatory factor-3 activation by hepatitis C virus
core protein basic amino acid region 1
Kazuaki Inoue a,b, Kyoko Tsukiyama-Kohara a,c,d, Chiho Matsuda a, Mitsutoshi Yoneyama e, Takashi Fujita f,
Shusuke Kuge g, Makoto Yoshiba b, Michinori Kohara a,⇑
aDepartment of Microbiology and Cell Biology, The Tokyo Metropolitan Institute of Medical Science, 2-1-6 Kamikitazawa, Setagaya-ku, Tokyo 156-0057, Japan
bDivision of Gastroenterology, Showa University Fujigaoka Hospital, 1-30 Aoba-ku, Fujigaoka, Yokohama 227-8501, Japan
cDepartment of Experimental Phylaxiology, Faculty of Life Sciences, Kumamoto University, 1-1-1 Honjo, Kumamoto City, Kumamoto 860-8556, Japan
d Joint Faculty of Veterinary Medicine, Kagoshima University, 1-21-24 Korimoto, Kagoshima City, Kagoshima 890-0065, Japan
eMedical Microbiology Research Center, Chiba University, 1-8-1 Inohana Chuo-Ku, Chiba-City, Chiba 260-8673, Japan
f Laboratory of Molecular Genetics, Institute for Virus Research, Kyoto University, Kyoto 606-8507, Japan
g Laboratory of Microbiology, Tohoku Pharmaceutical University, Komatsushima, Aoba-ku, Sendai 981-8558, Japana r t i c l e i n f o
Article history:
Received 17 October 2012
Available online 30 October 2012
Keywords:
Hepatitis C virus
IRF-3
Core protein
Type I interferon signaling
Basic amino acid region 1
Interferon beta0006-291X/ 2012 Elsevier Inc. Open access under CC B
http://dx.doi.org/10.1016/j.bbrc.2012.10.079
⇑ Corresponding author. Fax: +81 3 5316 3137.
E-mail address: kohara-mc@igakuken.or.jp (M. Koa b s t r a c t
Interferon regulatory factor-3 (IRF-3), a key transcriptional factor in the type I interferon system, is fre-
quently impaired by hepatitis C virus (HCV), in order to establish persistent infection. However, the exact
mechanism by which the virus establishes persistent infection has not been fully understood yet. The
present study aimed to investigate the effects of various HCV proteins on IRF-3 activation, and elucidate
the underlying mechanisms. To achieve this, full-length HCV and HCV subgenomic constructs corre-
sponding to structural and each of the nonstructural proteins were transiently transfected into HepG2
cells. IFN-b induction, plaque formation, and IRF-3 dimerization were elicited by Newcastle disease virus
(NDV) infection. The expressions of IRF-3 homodimer and its monomer, Ser386-phosphorylated IRF-3,
and HCV core protein were detected by immunoﬂuorescence and western blotting. IFN-b mRNA expres-
sion was quantiﬁed by real-time PCR (RT-PCR), and IRF-3 activity was measured by the levels of IRF-3
dimerization and phosphorylation, induced by NDV infection or polyriboinosinic:polyribocytidylic acid
[poly(I:C)]. Switching of the expression of the complete HCV genome as well as the core proteins, E1,
E2, and NS2, suppressed IFN-bmRNA levels and IRF-3 dimerization, induced by NDV infection. Our study
revealed a crucial region of the HCV core protein, basic amino acid region 1 (BR1), to inhibit IRF-3 dimer-
ization as well as its phosphorylation induced by NDV infection and poly (I:C), thus interfering with IRF-3
activation. Therefore, our study suggests that rescue of the IRF-3 pathway impairment may be an effec-
tive treatment for HCV infection.
 2012 Elsevier Inc. Open access under CC BY-NC-ND license.1. Introduction
Hepatitis C virus (HCV), a ﬂavivirus comprising a positive-sense,
single-stranded RNA (ssRNA) of approximately 9.6 kb [1], causes
persistent disease in infected individuals, possibly leading to
chronic liver injury [2]. Despite the approximately 170 million
individuals worldwide suffering from HCV infection that ranges
from chronic hepatitis to hepatocellular carcinoma (HCC) [3,4],
the exact mechanism by which the virus establishes persistent
infection is not fully resolved.
The innate immune system is activated immediately upon
infection as the ﬁrst line of host defense against invading patho-
gens, with type I interferon (IFN) signaling being the crucial stepY-NC-ND license. 
hara).in the antiviral response [5]. The IFN system is, therefore, a prime
target of HCV and other viruses in order to establish persistent
infections [6], wherein the disruption of the type I IFN-activation
pathway forms the most efﬁcient strategy for HCV. Studies on
HCV IFN-interference mechanisms have revealed that the HCV
proteins NS5A and E2 selectively inhibit the double-stranded
RNA-activated protein kinase (PKR) [7,8], an IFN-inducible antiviral
molecule that controls transcription and translation [6]. IFN-b, a
crucial molecule in type I IFN signaling, is regulated by several
cellular factors associated with the activation of interferon regula-
tory factor-3 (IRF-3), leading to its rapid induction following viral
infection [9,10]. However, IFN-b induction is impaired in HCV-
infected cells, thus resulting in the disruption of IFN downstream
signaling cascade [11].
IRF-3, a key constitutively expressed transcriptional factor
localized in the cytoplasm in its inactive form [9], is activated upon
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transcriptional factor for positive regulatory domain (PRD) I of the
IFN-b promoter. IRF-3 activation also induces phosphorylation of
Ser385 and Ser386 or the serine/threonine (Ser/Thr) cluster be-
tween amino acids (aa) 396 and 405 (located at the C-terminus
of IRF-3), a step that is essential for dimerization and nuclear
translocation.
A previous study by Foy et al. showed that the NS3/4A serine
protease derived from a subgenomic replicon participates in the
suppression of the cellular pathway that activates IRF-3 [12]. The
NS3/4A protein of HCV disrupts signaling of the double-stranded
RNA (dsRNA) receptors, retinoic acid-inducible gene-I (RIG-I), and
Toll-like receptor 3 (TLR3) by inducing proteolysis of interferon
promoter stimulator-1 (IPS-1) [13–15] and Toll/interleukin-1
receptor (TIR) domain-containing adaptor protein inducing IFN-b
(TRIF) [16], as well as by suppressing the downstream activation
of IFN-b [13].
In view of the above observations and the emerging data on the
role of HCV in regulating the IRF-3 pathway by additionalFig. 1. (A) Structures of the conditional expression vectors for HCV RNAs and proteins. Th
among the 3 clones were used to construct HCR6-Rz (nt 1–9611). HCR6-Fse clone harbore
lacked nucleotides 155–1967. They were ﬂanked with ribozyme (Rz) and hepatitis D viru
loxP switching expression cassette, which consisted of the neomycin resistance gene, as
HCR6-Rz, HCR6-Fse, and HCR6-Age before and after the expression of the HCV protein. The
RT-PCR. (C) Efﬁciency of NDV plaque formation. Plaque assays were performed on Ver
expression of the HCV protein. The plaque numbers were counted 3 days after NDV in
genome divided by the plaque numbers before the expression of the HCV genome. (
inoculation. Day 0, before the expression of the HCV genome; Day 48, after the expression
in each of the 3 HCV-expressing systems. p.i.h., post-inoculation hour.mechanisms, we aimed to investigate the effects of various HCV
proteins on IRF-3 activation, and further elucidate the underlying
novel mechanisms.2. Material and methods
2.1. Transient expression of the HCV core proteins E1, E2, and NS3-4A
HepG2 cells were transfected to express E1, E2, or NS3-4A HCV
core protein under the control of EF promoter (Invitrogen). The
HCV core expression vectors were derived from HCR6 (genotype
1b), HCR24-12K (genotype 2a), or HCR24-12Q (genotype 2a). The
E1, E2, and NS3 clones derived from HCR6 contained either the
full-length cDNAs encoding the core protein or 1 of the 3 different
deletions (deletion mutants), each of which lacked 1 of the 3 basic
amino acid regions (BR), BR1 deletion (aa 4–14), BR2 deletion (aa
37–44), and BR3 deletion (aa 57–72) [17]. HepG2 cells were trans-
fected with 4 lg of the core cDNA (amino acids 1–191), E1 (aminoe cDNA clones that displayed highest level of homology to the consensus sequences
d a termination codon introduced at nucleotide 3606 and truncated HCR6-Age clone
s ribozyme (HDV-Rz) sequences under the control of the CAG promoter in the Cre/
a stuffer region ﬂanked by the loxP sequence. (B) IFN-b mRNA levels in the cell lines
results are expressed as copy numbers per microgram of total RNA, as quantiﬁed by
o cells for NDV infectivity in HCR6-Rz, HCR6-Fse, or HCR6-Age before and after the
oculation. The ratio indicates the plaque numbers after the expression of the HCV
D) Suppression of IFN-b mRNA induction by HCV expression, 18 days after NDV
of the HCV genome. The results are expressed relative to the levels on Day 0 (100%)
Fig. 2. (A) HCV inhibition of IRF-3 nuclear translocation. IRF-3 is a constitutively
expressed transcriptional factor that localizes in the cytoplasm in a diffuse manner,
when inactive. After NDV inoculation and prior to the expression of the HCV
genome, IRF-3 translocated to the nucleus but was retained at a perinuclear site in
the HCR6-Rz-expressing cells (Day 48). IRF-3 colocalized with the HCV core protein.
(B–D) Suppression of IRF-3 dimerization by HCV expression. The dimeric and
monomeric forms of IRF-3 were detected by western blotting on native PAGE gels.
The inﬂuence of (B) HCR6-Rz expression, (C) HCR6-Fse expression, and (D) HCR6-Age
expression on IRF-3 dimerization is shown. NDV was used to induce IRF-3
dimerization.
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1027–1711), or the core regions lacking the BR, in 35-mm dishes,
by using Lipofectamine 2000 (Invitrogen) at 37 C for 6 h. The med-
ium was subsequently replaced with normal culture medium, and
the cells were harvested after 48 h.
2.2. Newcastle disease virus (NDV) infection and addition of
polyriboinosinic:polyribocytidylic acid [poly(I:C)]
NDV (Miyadera strain) was propagated from swabs by using the
embryonated egg culture method, as described in the Supplemen-
tary methods.
Poly(I:C) (20 lg/well; GE Healthcare) was added to HepG2 cells
in 35-mm dishes, 48 h after transfection with the core expression
vector derived from HCR6 (genotype 1b).
2.3. Native PAGE of IRF-3 and phosphorylated IRF-3
Cells were lysed in 30 lL of lysis buffer (50 mM Tris–HCl [pH
8.0], 1% NP-40, 150 mM NaCl, 100 lg/mL leupeptin, 1 mM PMSF,
5 mM Na3VO4), mixed vigorously, and centrifuged at 15,000 rpm
for 10 min; the supernatant was isolated. Total protein samples
(10 lg) were electrophoresed on a 7.5% native PAGE gel (Bio-Rad
Laboratories) and transferred onto a PVDF membrane. IRF-3
homodimer and its monomer and Ser386-phosphorylated IRF-3
were detected by western blotting using polyclonal rabbit antibod-
ies, anti-human IRF-3 (1:1000) [18] and, anti-human Ser386-phos-
phorylated IRF-3 (1:10,000), respectively. Detection was achieved
by enhanced chemiluminescence (ECL; Amersham, UK) according
to the manufacturer’s instructions. The rabbit anti-human IRF-3
and anti-human Ser386-phosphorylated IRF-3 antibodies were de-
scribed previously [19].
2.4. Quantiﬁcation of IFN-b gene expression
IFN-b mRNA expression was quantiﬁed by using real-time PCR
(RT-PCR) as described previously [20] and Supplementary methods
using the following primers and probes: sense (50-CCATCTATGA
GATGCTCCAGAA-30), antisense (50-TTTTCTTCCAGGACTGTCTTCA-
GA-30) and probe (50-AGCACTGGCTGGAATGAGACTATTGTTG-30).
3. Results
3.1. Induction of IFN and IRF-3 by HCV-Rz
To evaluate the effect of HCV gene persistent expression, cell
lines expressing the HCV genomes in a Cre/loxP expression system
[20] were established by transfecting the full-genome HCV (HCR6-
Rz); core, E1, E2, and NS2 (HCR6-Fse); and E2NS5b (HCR6-Age)
(Fig. 1A) clones into HepG2 cells. Of the 3 HCV expression systems,
only HCR6-Rz transiently induced endogenous IFN-b expression
(Fig. 1B). No endogenous IFN-b was detected by RT-PCR on Day 0
or Day 48 (long culture; LC) [21] in any of the 3 systems (Fig. 1B).
3.2. Effect of HCV expression on NDV infection and IFN-b induction
Further, we examined whether the persistent expression of HCV
genome inﬂuenced the plaque formation activity of NDV in HCR6-
Rz-, HCR6-Fse-, and HCR6-Age-expressing cell lines. Prior to the
expression of HCV proteins, the plaque numbers were similar
across all the cell lines (Fig. 1C). Expression of HCV proteins for
more than 48 days [21] increased plaque numbers in the HCR6-
Rz- and HCR6-Fse-expressing cells from 7- to 8-fold (Fig. 1C); how-
ever, plaque numbers in the HCR6-Age-expressing cells remained
constant. These ﬁndings thus indicate that HCV structural proteinsinterfered with the induction of IFN-b mRNA, after NDV infection
(18 h post-infection). Therefore, we measured IFN-b mRNA levels
in the 3 cell lines, HCR6-Rz, HCR6-Fse, and HCR6-Age, by RT-PCR be-
fore (Day 0) and after (Day 48) inoculation with NDV (Fig. 1D). The
mRNA expression of IFN-bwas not observed prior to NDV infection
in any of the 3 cell lines (Day 0). Notably, after 18 h of NDV
inoculation and prior to the expression of various HCV proteins
(Day 0), the levels of IFN-b mRNA transcription were similar
among HCR6-Rz-, HCR6-Fse-, and HCR6-Age-expressing cell lines
(Fig. 1D). Following HCV protein expression, the induced IFN-b
mRNA expression was reduced to 20% in both HCR6-Rz- and
HCR6-Fse-expressing cell lines. However, IFN-b mRNA expression
remained constant in the HCR6-Age-expressing cell line.
Fig. 3. (A) Structures of the HCR6 core, E1, and E2 expression vectors encoding the HCV core (aa 1–191), E1 (amino acids 192–383), and E2 (amino acids 384–809) proteins,
respectively, under the control of the EF1 promoter. (B) Left panel, IRF-3 dimerization induced by NDV before transfection with the expression vectors; right panel, IRF-3
dimerization induced by NDV after transfection with the expression vectors. (C) IFN-b mRNA induction levels at 12 and 18 h after NDV inoculation into HepG2 cells
transfected with the vector alone, core, E1, or E2 proteins. The results are expressed relative to the induction levels of IFN-b in HepG2 cells transfected with the vector alone
(100%), for post-inoculation, each time. (D) IRF-3 dimerization on administration of 10 mg/mL poly(I:C) before the expression (Day 0), and at 2, 4, 8, and 12 h after the
expression of the HCV core (pEF-Core) or vector plasmid DNA. (E) Effects of the expression of vector (lane 1), R6 core (lane 2), R24 core (lane 3), R24 core (Q12K) (lane 4), R6-
NS3-4A (lane 5), N1-NS3-4A (lane 6), and mock control (lane 7) on IRF-3 dimerization (upper column a) and phosphorylation of serine residue at amino acid 386 in IRF-3
(lower column b), after infection with NDV for 18 h. F. Effects of the expressions of R6-C, R24-C, R24-C(Q12K), and R6-NS3 on IFN-b induction, 18 h after NDV inoculation. The
IFN-b mRNA levels were assayed by RT-PCR. The results are expressed relative to the induction levels of IFN-b in HepG2 cells transfected with the vector alone (100%).
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dimerization by NDV
The effect of HCV expression on cellular localization of IRF-3
was analyzed in HCR6-Rz-expressing cells infected with NDVbefore (Day 0) and after LC (Fig. 2A). Prior to NDV infection, IRF-
3 was detected in the cytoplasm by immunoﬂuorescence. Notably,
after 18 h of NDV inoculation and prior to HCR6-Rz protein expres-
sion, when IFN-b induction and IRF-3 dimerization were maximal,
a substantial amount of IRF-3 translocated to the nucleus.
Fig. 4. (A) Structures of the HCR6 core, E1, and E2 expression vectors carrying the
complete core, BR1 deletion (aa 4–14), BR2 deletion (aa 37–44), and BR3 deletion
(aa 57–72). (B) Western blotting to conﬁrmed the expression of the mutated core
proteins. (C) Effects of the expression of various mutated core proteins on IRF-3
dimerization and IRF-3 phosphorylation at Ser386, 18 h after NDV inoculation. (D)
Effects of the expression of each type of core protein region on IFN-b mRNA
synthesis, 18 h after NDV inoculation. The results are expressed relative to the
induction levels of IFN-b in HepG2 cells transfected with the vector alone (100%).
IFN-b mRNA levels were assayed by RT-PCR.
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ence of HCV proteins (Fig. 2A) and resulted in the co-localization
of the HCV core protein with IRF-3 at perinuclear sites (Fig. 2A,
superimposed image of IRF-3 and core protein immunostaining).
To elucidate the mechanism underlying the suppression of IFN-
b mRNA in HCR6-Rz- and HCR6-Fse-expressing cells, we examined
the effect of HCV expression on IRF-3 dimerization after NDV infec-
tion (Fig. 2B). Interestingly, the levels of IRF-3 dimerization peaked
at 12–18 h after NDV infection in the 3 cell lines lacking HCV
expression (Day 0; Fig. 2). However, in the HCR6-Rz- and HCR6-
Fse-expressing cell lines, IRF-3 dimerization was found to be signif-
icantly reduced, (Fig. 2B and C) when compared to that in the
HCR6-Age-expressing cells (Fig. 2D).
3.4. Identiﬁcation of the HCV genome region responsible for the
inhibition of IRF-3 dimerization and IFN-b induction
To identify the HCV genome region responsible for suppression
of IRF-3 dimerization, HepG2 cells were transfected to express the
HCV core regions derived from HCR6, E1, or E2 (genotype 1b;
Fig. 3A). Protein expression was conﬁrmed by western blotting
(data not shown). The HCV core protein suppressed IRF-3 dimer-
ization, but E1 and E2 expressions had no effect on the dimeriza-
tion (Fig. 3B). Expression of E1, E2, or the vector alone did not
alter the levels of IFN-b mRNA induced by NDV infection in HepG2
cells (Fig. 3C), but signiﬁcantly reduced IFN-b mRNA levels at both
12 and 18 h after infection (Fig. 3C).
3.5. Effect of HCV core protein expression on IRF-3 dimerization
through TLR3
Among the synthetic dsRNAs, poly(I:C) is a potent inducer of
IFN-b through TLR3. Accordingly, HepG2 cells transfected with
poly(I:C) and the vector control (pEF1-vector) showed IRF-3 dimer-
ization (Fig. 3D). In contrast, IRF-3 dimerization was suppressed in
HepG2 cells expressing the HCV core protein albeit the induction of
IFN-b mRNA following poly(I:C) expression (data not shown).
3.6. Effect of the HCV core protein NS3 and core proteins derived from
genotype 2a on IRF-3 dimerization, compared to proteins derived from
genotype 1b
Further, we investigated whether the HCV core protein NS3 and
core proteins derived from other genotypes exerted the same ef-
fects on IRF-3 after 18 h of NDV infection. The core proteins derived
from genotypes 1b (R6) and 2a (R24-12Q and R24-12K) suppressed
IRF-3 dimerization in cells infected with NDV (Fig. 3E(a)). In con-
trast, IRF-3 dimerization remained unaltered in the presence of
R6 clone NS3 protein, but was suppressed by the N clone NS3 pro-
tein. Thus, NS3-4A protein of R6 clone suppressed IRF-3 dimeriza-
tion to a relatively lesser extent compared to that of the N1 strain.
Similar results were obtained for the phosphorylation at Ser386 in
IRF-3 (Fig. 3E(b)). The IFN-b mRNA transcription was quantiﬁed in
HepG2 cells by RT-PCR after transfection with these expression
vectors (Fig. 3F).
3.7. Identiﬁcation of the HCV core region responsible for suppressing
IRF-3 dimerization
We sought to identify the region of the HCV core protein
responsible for suppressing IRF-3 dimerization. Expression vec-
tors encoding the entire HCV core or the core region lacking 1
of the 3 basic amino acid regions (BR) that inﬂuenced nuclear
translocation [17] were transfected into HepG2 cells, and the ef-
fects on IRF-3 dimerization were examined (Fig. 4A). Proteinexpression of the core and the deletion mutants (BR1, BR2, and
BR3) was conﬁrmed by western blotting (Fig. 4B). IRF-3
dimerization, phosphorylation at Ser386 of IRF-3, and induction
of IFN-b mRNA were suppressed in HepG2 cells expressing the
entire core, a deletion of BR2, or a deletion of BR3 (Fig. 4C),
but not in cells expressing the BR1-deleted HCV core regions
(Fig. 4C and D).
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The present study indicates that the HCV core protein inhibits
IRF-3 dimerization, IRF-3 phosphorylation at Ser386, and IFN-b
induction. In addition, our study showed that the effect of the core
protein derived from genotype 1b was similar to that of the core
protein derived from genotype 2a, indicating that the inhibitory ef-
fect of the core protein might be effective in several genotypes of
HCV. These ﬁndings are corroborated by a previous study by Foy
et al. [12] who showed that HCV NS3/4 disrupts virus-associated-
kinase-mediated IRF-3 activation, which further results in the
suppression of IRF-3 phosphorylation, nuclear translocation, and
IRF-3-dependent ISRE/PRDI activation. These ﬁndings indicate that
attenuation of the IFN system was achieved through NS3/4A
proteins via the interference of IRF-3 activation, thus strengthening
our results, which show the potential of HCV core protein to
interfere with IRF-3 activation in promoting persistent infection.
Furthermore, the present study showed that the N-terminal
region of the core protein and BR-1 domain in particular are
responsible for inactivating IRF-3. The N-terminal region (amino
acids 1–59) of the HCV core protein has been identiﬁed as the
binding region for a DEAD box protein (DDX3) [22]. Human
DDX3, a putative RNA helicase, is a member of the highly con-
served DEAD box subclass that includes the expression of murine
PL10, Xenopus An3, and yeast Ded 1 proteins. Recently, expression
of DDX3 was found to enhance IFN-b promoter induction by TBK1/
IKKe, whereas silencing of DDX3 inhibited IFN-b promoter and
virus- or dsRNA-induced IRF-3 activation [23]. It was shown that
Vaccinia virus K7 protein also binds to DDX3 and inhibits pattern
recognition receptor-induced IFN-b induction by preventing
TBK1/IKKe-mediated IFN-b induction via impaired TBK1/IKKe-
induced activation of IRF-3 [23]. A previous study by Oshiumi
et al. showed that DDX3 C-terminal region (amino acids
622–662) directly binds to the IFN-beta promoter stimulator-1
(IPS-1) CARD-like domain [24] as well as the N-terminal HCV core
protein [36]. The present study demonstrated that the expression
of the core protein decreased the levels of DDX3 expression (data
not shown). This is in agreement with the result of a previous
study, which showed that DDX3 is downregulated in HCV-
associated hepatocellular carcinoma (HCC) and silencing of DDX3
accelerates cell growth [25]. Collectively, these ﬁndings suggest
that DDX3 may be the target of the core protein for inhibiting
IRF-3 activation.
In conclusion, our study revealed a crucial region of the HCV
core protein, basic amino acid region 1, to interfere with IRF-3
activation and thereby inhibit the IFN signaling cascades.
Therefore, the inhibitory effects that result in the IRF-3 pathway
impairment could be rescued by deleting the basic region 1 of core
protein, thus suggesting that it might be an effective treatment for
HCV infection. Future studies involving DDX3 modiﬁcation by the
HCV core protein may be interesting to explore the cell
growth-dysregulation mechanisms.
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